Phacilitate Leaders Forum

Sponsors & Exhibitors

Oxford BioMedica

Associate Sponsor

Oxford BioMedica is a leading gene-based biopharmaceutical company developing innovative medicines to improve the lives of patients with high unmet medical needs. We have established platform technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and is also widely used in the ex-vivo cell therapy arena.

Oxford BioMedica's product portfolio is focused on high value, growing markets. These include gene therapy products engineered to treat Parkinson's disease (preclinical, Phase I/II), Motor Neurone Disease (preclinical) and ocular diseases (preclinical), especially retinal diseases (Phase I and Phase I/II).

The Company also has a MHRA certified GMP manufacturing capability to produce Advanced Medicinal Products (AMP). In particular our focus is on viral manufacturing and development.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd